Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer ...

About TNX-1700 TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed ...

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming ...

A copy of the poster is available on the Company’s website.

Labroots is excited to bring leading academia and industry experts, research scholars, healthcare and medical professionals, clinicians, oncologists, and top scientists under one virtual roof for the ...

WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences (COGT), Inc. , a biotechnology company focused on developing precision therapies for genetically defined ...

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming ...

Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent degraders that address the limitations of first-generation ...

From smart pill bottles that help people remember to take their meds to calls for better menopausal symptom relief for women with breast cancer to intriguing hints at what drives dormant tumor cells ...

Farnaz Mehran, Myra Rana, and Amy Trinh, third year dental students, recently participated in UAB O’Neal Comprehensive Cancer Center’s ENRICH Program. ENRICH Farnaz Mehran at UAB ENRICH symposium with ...

Labroots is excited to bring leading academia and industry experts, research scholars, healthcare and medical professionals, clinicians, oncologists, and top scientists under one virtual roof for the ...